Recent Analysts’ Ratings Updates for Guardant Health (GH)

Several analysts have recently updated their ratings and price targets for Guardant Health (NASDAQ: GH):

• 9/15/2026 – Guardant Health had its “overweight” rating reaffirmed by Piper Sandler.
• 9/10/2026 – Guardant Health had its “outperform” rating reaffirmed by Sanford C. Bernstein. They now have a $210.00 price target on the stock.
• 9/9/2026 – Guardant Health had its price target raised by UBS Group AG from $175.00 to $225.00. They now have a “buy” rating on the stock.
• 9/8/2026 – Guardant Health is now covered by Rothschild & Co Redburn. They set a “buy” rating and a $203.00 price target on the stock.
• 9/8/2026 – Guardant Health is now covered by Rothschild & Co Redburn. They set a “buy” rating and a $203.00 price target on the stock.
• 9/2/2026 – Guardant Health had its “buy” rating reaffirmed by BTIG Research. They now have a $195.00 price target on the stock.
• 8/25/2026 – Guardant Health had its “buy” rating reaffirmed by TD Cowen.
• 8/4/2026 – Guardant Health had its price target raised by Stephens from $170.00 to $195.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Guardant Health had its price target raised by Piper Sandler from $135.00 to $193.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Guardant Health had its price target raised by Morgan Stanley from $175.00 to $185.00. They now have an “overweight” rating on the stock.
• 7/31/2026 – Guardant Health had its price target raised by Royal Bank Of Canada from $185.00 to $200.00. They now have an “outperform” rating on the stock.
• 7/31/2026 – Guardant Health was given a new $210.00 price target by Royal Bank Of Canada.
• 7/31/2026 – Guardant Health had its price target raised by TD Cowen from $200.00 to $210.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Guardant Health had its price target raised by Stifel Nicolaus from $130.00 to $180.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Guardant Health had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $210.00 price target on the stock.
• 7/31/2026 – Guardant Health had its price target raised by Mizuho from $175.00 to $200.00. They now have an “outperform” rating on the stock.
• 7/31/2026 – Guardant Health had its price target raised by BTIG Research from $190.00 to $195.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Guardant Health had its price target raised by Barclays PLC from $150.00 to $200.00. They now have an “overweight” rating on the stock.
• 7/31/2026 – Guardant Health had its price target raised by JPMorgan Chase & Co. from $185.00 to $195.00. They now have an “overweight” rating on the stock.

Insider Activity at Guardant Health

In other news, insider Chris Freeman sold 63,605 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $169.58, for a total value of $10,786,135.90. Following the completion of the transaction, the insider owned 65,374 shares in the company, valued at $11,086,122.92. This trade represents a 49.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ian T. Clark sold 14,180 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $158.92, for a total value of $2,253,485.60. Following the transaction, the director directly owned 2,975 shares of the company’s stock, valued at approximately $472,787. This trade represents a 82.66% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 438,755 shares of company stock worth $69,353,307 in the last quarter. 5.60% of the stock is owned by company insiders.

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based diagnostic tests designed to help detect cancer, guide treatment decisions and monitor patients over time. Its liquid biopsy technologies analyze tumor-related signals in blood, reducing the need for tissue biopsies in certain clinical and research settings.

The company’s products include Guardant360 tests, which profile advanced cancers and can help identify potentially actionable genomic alterations; Guardant Reveal, which is used to assess residual disease and recurrence risk; and Guardant Shield, a blood-based screening test for colorectal cancer.